Recent secondary market transactions have driven Neuralink valuations to $42–59.8 billion as of early October 2026, up sharply from the $9–9.7 billion post-money Series E close in mid-2025, reflecting robust trader appetite for Musk-associated neurotechnology assets amid limited primary funding updates. Clinical progress remains early, with roughly two dozen trial participants focused on paralysis and vision applications, while pre-IPO perpetual contracts on venues like Gate indicate ongoing liquidity and sentiment around the $45–60 billion range. With resolution just weeks away, any incremental trial data releases, investor indications near $60 billion, or broader risk-on flows tied to Treasury yields and equity benchmarks could influence final marks before October 31.